Related Experiment Videos
[Antimicrobial combination therapy]
1Klinische Abteilung für Allgemeine Innere Medizin, Klinische Infektiologie und Immunologie, Universitätsklinik für Innere Medizin, Anichstrasse 35, A-6020 Innsbruck. guenter.weiss@uibk.ac.at
Wiener Medizinische Wochenschrift (1946)
|May 27, 2003
Summary
Antimicrobial combination therapy is common but lacks strong evidence. While beneficial in some severe infections, it carries risks and requires more research for optimal use.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Microbiology
Context:
- Antimicrobial combination therapy is widely used despite limited high-quality clinical trial data.
- Rationale includes treating polymicrobial, severe, or immunocompromised patient infections, preventing resistance, and exploiting synergistic effects.
- Current evidence supports combination therapy in enterococcal endocarditis and Gram-negative rod infections (especially Pseudomonas) in severely immunocompromised patients.
Purpose:
- To review the current evidence and rationale for antimicrobial combination therapy.
- To highlight the benefits and risks associated with using multiple antimicrobial agents.
- To emphasize the need for well-designed prospective studies to guide clinical practice.
Summary:
- Prospective studies show combination therapy superiority in specific infections like enterococcal endocarditis and Gram-negative rod infections.
- Evidence for efficacy in staphylococcal infections is limited, despite clinical indications.
- Potential risks include antagonism, cumulative side effects, and resistance pathway stimulation.
Impact:
- Highlights the gap between empirical use and evidence-based practice in antimicrobial combination therapy.
- Underscores the need for rigorous research to define the true benefits and risks.
- Informs judicious use of combination therapy, balancing potential advantages against adverse effects and resistance development.